Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 7.01, 9.01 · 8-K

Biofrontera Inc.

BFRINASDAQEQUITYCurrent

Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On February 9, 2026, Biofrontera Inc. issued a press release announcing the results in its Phase 3 study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk. The full text of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.…

Filed Feb 9, 2026Accepted Feb 9, 2026, 9:20 AM ESTCIK 1858685Accession 0001493152-26-005717
Share

Company context

Current securities

Historical securities (1)

Recent company filings

  1. 10-Q filingNov 13, 2026
  2. SCHEDULE 13G/A - filed by Rosalind Advisors, Inc. regarding Biofrontera Inc.Nov 13, 2026
  3. Results of Operations and Financial ConditionNov 13, 2026
  4. 25-NSE - filed by Nasdaq Stock Market LLC regarding Biofrontera Inc.Oct 30, 2026
  5. Other EventsSep 14, 2026

Registered securities in this filing

Biofrontera Inc. · 8-K · Filed 2026-02-09

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common stock, par value $0.001 per share

Symbol
BFRI
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: From2026-02-092026-02-09_custom_CommonStockParValue0.001PerShareMember

Dimensions: us-gaap:StatementClassOfStockAxis

Preferred Stock Purchase Rights

Symbol
No trading symbol declared
Exchange
NASDAQ
Classification
RIGHT
Filing context

Context: From2026-02-092026-02-09_custom_PreferredStockPurchaseRightsMember

Dimensions: us-gaap:StatementClassOfStockAxis

No-trading-symbol fact: true

Warrants to purchase common stock

Symbol
BFRIW
Exchange
NASDAQ
Classification
WARRANT
Status
Historical · closed Nov 2, 2026
Filing context

Context: From2026-02-092026-02-09_custom_WarrantsToPurchaseCommonStockMember

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000149315226005717 · 3 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On February 9, 2026, Biofrontera Inc. issued a press release announcing the results in its Phase 3 study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk. The full text of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information contained in Item 7.01 of this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 (by filename) ex99-1.htm

Exhibit 99.1 Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint Study findings met its primary endpoint and showed highly statistically significant superiority for Ameluz® vs. vehicle gel (p<0.0003) Actinic keratosis (AK) is the most common skin condition diagnosed by US dermatologists1 If left untreated, AK may progress to squamous cell carcinoma2,3 WOBURN, Mass. (February 9, 2026) - Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced positive and statistically significant top-line results from its Phase 3 clinical trial evaluating Ameluz ® PDT with the red-light LED (RhodoLED ® ) platform for the treatment of mild to moderate actinic keratoses (AKs) on the extremities, neck, and trunk. The multicenter, randomized, double-blind, vehicle-controlled Phase 3 study evaluated the efficacy and tolerability of field-directed Ameluz ® PDT compared with vehicle PDT in patients with AKs located on the extremities, neck, and trunk.…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.